$158.65
$156.51
$167.39
$144.38
$374.2B
5.32%
This is a preview of the full version of Prosperse
Janssen-Cilag International NV announced new data from the OrigAMI-1 phase 1b/2 study, which showed that amivantamab combined with chemotherapy (mFOLFOX6 or FOLFIRI) demonstrated promising, rapid, and durable anti-tumor activity in patients with RAS/BRAF wild-type metastatic colorectal cancer who ha...
Janssen-Cilag International Nv
Sep 16, 2024
Janssen-Cilag International NV, a Johnson & Johnson company, announced positive results from the Phase 2b SunRISe-1 study, showing an 84% complete response rate with their investigational TAR-200 monotherapy in patients with high-risk non-muscle-invasive bladder cancer who are Bacillus Calmette-Guér...
Janssen-Cilag International Nv
Sep 15, 2024
Amivantamab plus chemotherapy showed a positive overall survival trend and significant improvements in post-progression outcomes compared to chemotherapy alone in patients with previously treated EGFR-mutated non-small cell lung cancer.
Janssen-Cilag International Nv
Sep 14, 2024
The global bipolar disorder market is expected to grow from $5.2 billion in 2023 to $7 billion by 2033, driven by increasing prevalence, government initiatives, and technological advancements. However, side effects of medications and misdiagnosis pose challenges.
The Brainy Insights
Sep 13, 2024
Novavax, a vaccine maker, has received emergency use authorization from the FDA for its updated COVID-19 vaccine. However, the company is expected to play a secondary role in the market, and its long-term prospects remain uncertain due to its partnership with Sanofi and the development of its own pr...
Prosper Junior Bakiny
Sep 13, 2024
ONL Therapeutics, a clinical-stage biopharmaceutical company, has secured $65M in Series D financing led by Johnson & Johnson Innovation – JJDC, Inc. The funds will be used to advance the development of ONL1204 Ophthalmic Solution, a novel treatment for geographic atrophy associated with dry age-rel...
N/A
Sep 13, 2024
Date: Nov 6, 2024
Date: Nov 6, 2024
Date: Nov 6, 2024
Date: Nov 6, 2024
Date: Nov 6, 2024